Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.

JAMA Netw Open · 2023 · PMC10570888 · PMID 37824143

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The uptake rate of cancer biosimilars showed an increasing trend over time ( Figure 2 and eTable 15 in Supplement 1 ). eTable 16 in Supplement 1 shows the uptake rates of biosimilars for the 3 cancer drugs in the first and second year after launch and at the latest time (2022).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.